Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Guselkumab · Tremfya, CNTO-1959

Monoclonal antibody · Antagonist of interleukin-23 subunit alpha (p19) (IL23A) · developed by Janssen Biotech

Approved FDA, Jul 2017
JNJ Developer

What is Guselkumab?

Guselkumab is a human IgG1 lambda monoclonal antibody that selectively binds the p19 subunit of interleukin-23 and blocks its interaction with the IL-23 receptor, reducing release of proinflammatory cytokines and chemokines.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Tremfya, CNTO-1959, TREMFYA
Drug type
Monoclonal antibody
Targets
interleukin-23 subunit alpha (p19) (IL23A)
Mechanism
Antagonist of interleukin-23 subunit alpha (p19) (IL23A)
Pathways
IL-23 signaling, proinflammatory cytokine and chemokine release
Therapy area
Dermatology, Musculoskeletal
Developer
Janssen Biotech (JNJ)
FDA status
Approved as Tremfya (July 13, 2017), BLA761061 · FDA label
UNII
089658A12D

✅ FDA-approved uses

From the indications section of the FDA label (version of Jun 4, 2026). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Arthritis, Psoriatic

Other drugs acting on IL23A

More from Janssen Biotech

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the JNJ page.

Follow JNJ, the company behind Guselkumab

See JNJ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

JNJ catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.